A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
This similarity suggests that the two enzymes originally arose due to gene duplication, and evolved over time to fill unique roles in the coagulation cascade. Clotting enzymes isolated from Limulus polyphemus and Tachypleus tridentatus exhibit similar properties, indicating high conservation of this enzyme throughout evolutionary divergence.
==== Israel ==== Dunkin' Donuts Israel (Hebrew: דאנקן דונאטס) was an Israeli franchise of the chain. Dunkin' Donuts Israel opened their first location in Israel in 1996 in Tel Aviv. Their main flagship store was located in Rabin Square, with their factory in Lod. Upon opening their first location, Dunkin' was a huge hit. When the original location opened, it broke Dunkin's own sales records by selling 3 million doughnuts in the first eight months. The chain's manager was quoted saying "Israelis do not stop eating doughnuts, They buy such quantities, quantities that we would never have believed they would buy. They buy boxes of 12, eat them here, and then buy more boxes to take home." In 2001, when Dunkin' Donuts Israel decided to close, the company had accumulated a large amount of debt. When the Second Intifada broke out, Israeli tourism slowed, and Dunkin' decided to close. Approximately $2 million was invested in Dunkin' Donuts Israel when it failed. At the peak, Dunkin' Donuts had 9 branches in Israel, short of their original goal of 15, including 3 in Jerusalem.
The United Kingdom dismissed the warnings of Winston Churchill and a few others about a continuing Marxist-Leninist threat, and opened trade relations and de facto diplomatic recognition in 1922. There was hope for a settlement of the pre-war Tsarist debts, but it was repeatedly postponed. Formal recognition came when the new Labour Party came to power in 1924. All the other countries followed suit in opening trade relations. Henry Ford opened large-scale business relations with the Soviets in the late 1920s, hoping that it would lead to long-term peace. Finally, in 1933, the United States officially recognized the USSR, a decision backed by the public opinion and especially by US business interests that expected an opening of a new profitable market. In the late 1920s and early 1930s, Stalin ordered Marxist-Leninist parties across the world to strongly oppose non-Marxist political parties, labour unions or other organizations on the left, which they labelled social fascists. In the usage of the Soviet Union, and of the Comintern and its affiliated parties in this period, the epithet fascist was used to describe capitalist society in general and virtually any anti-Soviet or anti-Stalinist activity or opinion. Stalin reversed himself in 1934 with the Popular Front program that called on all Marxist parties to join with all anti-Fascist political, labour, and organizational forces that were opposed to fascism, especially of the Nazi variety.
Sources: en.wikipedia.org
== Production == The Booth's beers are produced at four locations (The Booth's Pangyo Brewery, The Booth's Eureka Brewery, Brew Hub, and De Proefbrouwerij), on three continents (Asia, North America, and Europe). Production at Brew Hub has helped quintuple The Booth's production of their flagship beers, Kukmin IPA and Kieuk IPA. Its beers include Taedonggang Pale Ale: International Pale Ale, made in collaboration with Danish gypsy-brewery Mikkeller, and Kieuk Session IPA: Session India Pale Ale, made in collaboration with Kiha and the Faces, an indie music band from Korea. In October 2015, they acquired a brewing facility in Eureka, California, formerly owned by Lost Coast Brewery. In December 2020, the Eureka facility was shut down.
February 27, 2009: Finland Statistics Finland informs that Finland's gross domestic product diminished by 1.3% in the last quarter of 2008 from the previous quarter. The growth slowed down already in early 2008 and in the third quarter output diminished by 0.3% from the previous quarter.
=== Variants and subgroups === Regulators and clinical trials often use additional subgroups based on how active the disease is, even if there is no firm agreement on their definition. Examples are 'active MS', 'highly active MS' and 'rapidly evolving severe MS'. One definition of highly active MS is having an unchanged or increased number of relapses even after starting disease-modifying treatment. In addition, the term 'relapsing MS' is often used to denote people with relapsing-remitting MS as well as the subset of individuals with secondary progressive MS who still experience some relapses. The terms "benign MS" is sometimes used for people who have had MS for a long time (15 years or so) with few attacks and little disability. As people may still get worse, the term is discouraged. On the other hand, the term aggressive multiple sclerosis (previously known as "malignant multiple sclerosis") is used to describe people with MS having reached a significant level of disability in a short period. Atypical variants of MS have been described; these include tumefactive multiple sclerosis, Balo concentric sclerosis, and Marburg multiple sclerosis.
== Encoded split and pool synthesis == Although in the S&P synthesis a single compound forms on each bead its structure is not known. For this reason, encoding methods had been introduced to help to determine the identity of the compound contained in a selected bead. Encoding molecules are coupled to the beads in parallel with the coupling of the BBs. The structure of the encoding molecule has to be easier determined than that of the library member on the bead. Ohlmeyer et al. published a binary encoding method. They used mixtures of 18 tagging molecules that after cleaving them from the beads could be identified by Electron Capture Gas Chromatography. Nikolajev et al. applied peptide sequences for encoding Sarkar et al. described chiral oligomers of pentenoic amides (COPAs) that can be used to construct mass encoded OBOC libraries. Kerr et al. introduced an innovative kind of encoding. An orthogonally protected removable bifunctional linker was attached to the beads. One end of the linker was used to attach the non-natural BBs of the library while to the other end the encoding amino acid triplets were linked. One of the earliest and very successful encoding methods was introduced by Brenner and Lerner in 1992. They proposed to attach DNA oligomers to the beads for encoding their content. The method was implemented by Nielsen, Brenner, and Janda using the bifunctional linker of Kerr et al. to attach the encoding DNA oligomers. This made it possible to cleave down the compound with the DNA encoding oligomer attached to it.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.